Neutrophil-To-Lymphocyte Ratio as an Early Marker of Outcomes in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Nivolumab

International Journal of Clinical Oncology - Japan
doi 10.1007/s10147-018-1250-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

P2.01-112 Prognostic Value of Changes in Neutrophil-To-Lymphocyte Ratio in Patients With Lung Cancer Treated With Nivolumab

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Neutrophil-Lymphocyte Ratio Predicts Recurrence in Patients With Resected Stage 1 Non-Small Cell Lung Cancer

Journal of Cardiothoracic Surgery
CardiologyCardiovascular MedicineMedicinePulmonaryRespiratory MedicineSurgery
2018English

Neutrophil/Lymphocyte Ratio Predicts Chemotherapy Outcomes in Patients With Advanced Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2011English

Baseline Neutrophil-To-Lymphocyte Ratio (NLR) and Derived NLR Could Predict Overall Survival in Patients With Advanced Melanoma Treated With Nivolumab

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2018English

The Prognostic Impact of Neutrophil-To-Lymphocyte Ratio, Lymphocyte-To-Monocyte Ratio, and Platelet-To-Lymphocyte Ratio in Patients With Advanced Colorectal Cancer Treated With First-Line Chemotherapy

Przeglad Gastroenterologiczny
Gastroenterology
2018English

MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non‐Small Cell Lung Cancer Patients

Oncologist
Cancer ResearchMedicineOncology
2018English

Pseudo-Progression and the Neutrophil-To-Lymphocyte Ratio in Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors: A Case–Control Study

OncoTargets and Therapy
OncologyPharmacology
2019English

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

JAMA Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy